Clinical Trials on Paroxysmal Nocturnal Hemoglobinuria in Korea, Democratic People's Republic of

Total 63 results

Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, New Zealand, Korea, Republic of, Italy
BioCryst Pharmaceuticals

Terminated

BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy (REDEEM-2)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Malaysia, South Africa, Korea, Republic of
Alexion

Active, not recruiting

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Italy, Canada, Korea, Republic of, New Zealand, Spain, Turkey
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria

New Zealand, Korea, Republic of, Italy
Alexion Pharmaceuticals

Completed

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH

Korea, Republic of, Australia
Asan Medical Center

Completed

Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome

Myelodysplastic Syndromes | Leukemia | Nonmalignant Neoplasm | Paroxysmal Nocturnal Hemoglobinuria

Korea, Republic of
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Hong Kong, Hungary, Korea, Republic of, Malaysia, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy (APPOINT-PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

China, Germany, Singapore, Korea, Republic of, Italy, United Kingdom, Malaysia, France
Hoffmann-La Roche
Chugai Pharmaceutical

Active, not recruiting

Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria (COMPOSER)

Paroxysmal Hemoglobinuria, Nocturnal

France, Korea, Republic of, Italy, Japan, Germany, Hungary, Netherlands
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Taiwan, Singapore, Korea, Republic of, Malaysia
Alexion

Completed

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Korea, Republic of, Canada, France, Germany, Spain, United Kingdom, Japan, Australia, Italy, Netherlands
Alexion

Completed

ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Belgium, France, Italy, Japan, Spain, Taiwan, United Kingdom, United States, Canada, Czechia, Germany, Sweden, Singapore, Korea, Republic of, Russian Federation, Austria, Poland, Argentina, Australia, Brazil, Estonia, Malaysia, Mexico, Thaila... and more
Alexion Pharmaceuticals

Completed

Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria | PNH

Korea, Republic of, Canada, France, Germany, Spain, Taiwan, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment (APPLY-PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Italy, Japan, Taiwan, Germany, France, United Kingdom, Spain, Korea, Republic of, Czechia, Brazil, Netherlands, United States
BioCryst Pharmaceuticals

Active, not recruiting

Long-term Safety of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom, Hungary, France, Spain, Malaysia, South Africa, Korea, Republic of
Regeneron Pharmaceuticals

Terminated

REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.

Paroxysmal Nocturnal Hemoglobinuria

Hong Kong, Korea, Republic of, Malaysia, Hungary, Taiwan, United Kingdom
Regeneron Pharmaceuticals

Completed

Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

Paroxysmal Nocturnal Hemoglobinuria

Korea, Republic of, Taiwan, Malaysia, Hong Kong, Hungary, United Kingdom
Samsung Medical Center

Unknown

Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Hemoglobinuria, Paroxysmal

Korea, Republic of
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Long-term Safety, Tolerability, and Effectiveness of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (ACCESS-EXT)

Paroxysmal Nocturnal Hemoglobinuria

Taiwan, Korea, Republic of, Turkey, Spain, Thailand, Singapore, Japan, Canada, Malaysia, Poland, Italy
Apellis Pharmaceuticals, Inc.

Completed

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria

United States, France, Russian Federation, Korea, Republic of, Canada, Germany, Australia, Japan, Spain, Belgium, United Kingdom
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Korea, Republic of, Taiwan, Malaysia, Thailand, Romania, India, Mexico, Ukraine
AO GENERIUM

Completed

Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria® (NAP)

Paroxysmal Nocturnal Hemoglobinuria

Russian Federation
Novartis Pharmaceuticals

Recruiting

Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan. (APPULSE)

Paroxysmal Nocturnal Hemoglobinuria

France, Spain, Italy, Turkey, Germany, United States, Korea, Republic of, United Kingdom
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Thailand, Korea, Republic of, United Kingdom, Israel, Czechia, Greece, Poland, Brazil, Japan, Canada, Malaysia
Regeneron Pharmaceuticals

Recruiting

A C5 Inhibitor-controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy (ACCESS-1)

Paroxysmal Nocturnal Hemoglobinuria

Mexico, Korea, Republic of, Turkey, Italy, United Kingdom, Thailand, Poland, Singapore, Spain, Taiwan, Canada, Japan, United States, Malaysia, Greece, Romania, Hungary
Novartis Pharmaceuticals

Recruiting

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

United States, Korea, Republic of, Singapore, Germany, Taiwan, Italy, Turkey, France, Malaysia, Lithuania, Netherlands, United Kingdom, Japan, Czechia, Spain, China, Brazil
Hoffmann-La Roche
Chugai Pharmaceutical

Active, not recruiting

A Phase III Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors. (COMMODORE 2)

Paroxysmal Nocturnal Hemoglobinuria

Spain, Korea, Republic of, France, Sweden, Thailand, Malaysia, China, Turkey, Netherlands, Japan, Australia, United Kingdom, Germany, Brazil, Romania, Argentina, Poland, Greece, Hong Kong, Lithuania, Mexico, Philippines, Portugal, Sin... and more
Hoffmann-La Roche
Chugai Pharmaceutical

Recruiting

A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (COMMODORE 1)

Paroxysmal Nocturnal Hemoglobinuria

United States, Korea, Republic of, Spain, Germany, Estonia, Japan, Colombia, Saudi Arabia, Turkey, Brazil, France, Greece, Poland, Taiwan, Netherlands, Italy, Australia, Sweden, Singapore, Portugal, Hungary, Belgium, Canada, Czechia, Hong... and more
Alexion Pharmaceuticals, Inc.

Completed

Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Taiwan, Thailand, Korea, Republic of, Japan, Malaysia, Brazil, Germany, Israel, Czechia, Netherlands, Greece, United Kingdom, Canada, Poland
Cooperative Study Group A for Hematology

Completed

Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT (CyFluCyATG)

Bone Marrow Failure Syndromes

Korea, Republic of
Chonbuk National University

Unknown

Treatment of Posterior Canal Type of Benign Paroxysmal Positional Vertigo (PC-BPPV)

Benign Paroxysmal Positional Vertigo (BPPV)

Korea, Republic of
Yonsei University

Completed

The Effects of the Myofascial Trigger Point Injections on Pain and Sleep Disturbance in Patients With Nocturnal Leg Cramps With Trigger Points on Gastrocnemius Muscle

Nocturnal Leg Cramps

Korea, Republic of
Yonsei University

Recruiting

Clinical Usefulness of Virtual Ablation Guided Catheter Ablation of Atrial Fibrillation: Virtual Rotor Mapping and Catheter Ablation (CUVIA-AF II)

Paroxysmal Atrial Fibrillation

Korea, Republic of
Yong Seog Oh

Completed

Effect of Cavotricuspid Isthmus Ablation in Patients Without History of Typical Flutter During Ablation

Paroxysmal Atrial Fibrillation

Korea, Republic of
Pusan National University Hospital

Completed

Zero-fluoroscopic Cryoballoon Ablation

Atrial Fibrillation Paroxysmal

Korea, Republic of
Yonsei University

Completed

Comparison of Single Groin and Single Trans-septal Puncture and Conventional Bilateral Groin Puncture and Double Trans-septal Puncture in Catheter Ablation for Atrial Fibrillation

Paroxysmal Atrial Fibrillation

Korea, Republic of
Yonsei University

Completed

Botulinum Toxin Type A Injection Into the Gastrocnemius Muscle for Treatment of Nocturnal Calf Cramps in Patients With Lumbar Spinal Stenosis

Spinal Stenosis With Nocturnal Calf Cramps

Korea, Republic of
Yonsei University

Recruiting

Computed Tomogram Myocardial Thickness Map Guided pulmOnary Vein iSolaTion vs. Empirical Pulmonary Vein Isolation in Cryoballoon Ablation for Paroxysmal Atrial Fibrillation (UTMOST AF II)

Paroxysmal Atrial Fibrillation

Korea, Republic of
Yonsei University

Recruiting

Cryoballoon Pulmonary Vein Isolation vs. Radiofrequency Pulmonary Vein Isolation With Additional Right Atrial Linear Ablation for Paroxysmal Atrial Fibrillation: Prospective Randomized Trial (CRAPAF Trial)

Paroxysmal Atrial Fibrillation

Korea, Republic of
Korea University

Unknown

Efficacy of Pilsicainide After Radiofrequency Ablation of Paroxysmal Atrial Fibrillation

Paroxysmal Atrial Fibrillation

Korea, Republic of
Ferring Pharmaceuticals

Terminated

Study of Minirin Melt® in Adult Patients With Nocturia

Nocturia

Korea, Republic of
Seoul National University Hospital

Terminated

Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation

Atrial Fibrillation New Onset | Atrial Fibrillation Paroxysmal

Korea, Republic of
Seoul National University Hospital

Recruiting

Prognosis of Paroxysmal Kinesigenic Choreoathetosis in Korea

Paroxysmal Kinesigenic Choreoathetosis

Korea, Republic of
Seoul National University Hospital
Ferring Pharmaceuticals

Completed

The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patients With Nocturia

Nocturia

Korea, Republic of
Seoul National University Hospital

Completed

Necessity for Repetitive Education of Behavioral Modification

Patients Who Had the Urine Volume at Nighttime More Than One Third of Total Daily Urine Volume (NPU) and Voided More Than Two Times at Nighttime (Nocturia)

Korea, Republic of
Yonsei University

Completed

Effect of Baclofen Treatment on Nocturnal Muscle Cramps in Patients With Lumbar Spinal Stenosis: a Randomized Clinical Trial

Lumbar Spinal Stenosis With Nocturnal Calf Cramps

Korea, Republic of
Seoul National University Hospital

Completed

Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men

Nocturia

Korea, Republic of
Keimyung University Dongsan Medical Center

Completed

Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo

Benign Paroxysmal Positional Vertigo

Korea, Republic of
Asan Medical Center

Recruiting

Cardea SOLOTM for Paroxysmal Atrial Fibrillation Diagnosis in ESUS Patients With Left Atrial Enlargement

Embolic Stroke of Undetermined Source

Korea, Republic of
Ewha Womans University Mokdong Hospital
Ewha Womans University Seoul Hospital

Enrolling by invitation

Prospective Validation Study of AI-based Prediction Algorithm for the Prediction of Paroxysmal Atrial Fibrillation (PROVISION-AF)

Atrial Fibrillation Paroxysmal

Korea, Republic of

Clinical Trials on Paroxysmal Nocturnal Hemoglobinuria in Korea, Democratic People's Republic of

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations